Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15212467 | 0.89 | ALPL (0.55) | ALPLALDH1A1MAPTHIF1AEPAS1 | |
| SCHEMBL15211957 | 0.88 | ALPL (0.60) | ALPLALDH1A1MAPK1TSHRMAPT | |
| SCHEMBL15212056 | 0.86 | ALPL (0.58) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15212011 | 0.85 | ALPL (0.59) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15211975 | 0.85 | ALPL (0.57) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15212241 | 0.85 | ALPL (0.57) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15212047 | 0.84 | ALPL (0.56) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15212118 | 0.84 | ALPL (0.56) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL15211733 | 0.83 | ALPL (0.55) | ALPLALDH1A1MAPK1TSHRHIF1A | |
| SCHEMBL21226610 | 0.83 | ALPL (0.54) | ALPLALDH1A1MAPK1TSHRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023132214-A1 | CURABLE COMPOSITION AND CURED PRODUCT | 株式会社カネカ | 2023-07-13 | — | — | WO | disclosed |
| WO-2022071387-A1 | POLARIZING FILM, OPTICAL FILM, AND IMAGE DISPLAY DEVICE | 日東電工株式会社 | 2022-04-07 | — | — | WO | disclosed |
| US-11066509-B2 | Conductive paste composition, device comprising electrode formed from same, and method for producing conductive paste composition | KANEKA CORPORATION (JP) | 2021-07-20 | — | — | US | disclosed |
| WO-2021141037-A1 | METHOD FOR PRODUCING POLARIZING FILM | 日東電工株式会社 | 2021-07-15 | — | — | WO | disclosed |
| US-20210132274-A1 | CURABLE RESIN COMPOSITION FOR POLARIZING FILMS, POLARIZING FILM AND METHOD FOR PRODUCING SAME | NITTO DENKO CORPORATION (JP) | 2021-05-06 | — | — | US | disclosed |
| WO-2020196625-A1 | METHOD FOR MANUFACTURING POLARIZING FILM | 日東電工株式会社 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020196618-A1 | POLARIZING FILM MANUFACTURING METHOD | 日東電工株式会社 | 2020-10-01 | — | — | WO | disclosed |
| US-20200095370-A1 | CONDUCTIVE PASTE COMPOSITION, DEVICE COMPRISING ELECTRODE FORMED FROM SAME, AND METHOD FOR PRODUCING CONDUCTIVE PASTE COMPOSITION | KANEKA CORPORATION (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20200056051-A1 | CURABLE RESIN COMPOSITION FOR OPTICAL FILMS, OPTICAL FILM AND METHOD FOR PRODUCING SAME | NITTO DENKO CORPORATION (JP) | 2020-02-20 | — | — | US | disclosed |
| WO-2019187904-A1 | ALKALI DEVELOPING-TYPE PHOTOSENSITIVE RESIN COMPOSITION, DRY FILM, CURED PRODUCT AND PRINTED CIRCUIT BOARD | 太陽インキ製造株式会社 | 2019-10-03 | — | — | WO | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458147-B2 | Sulfonamide compounds and uses as TNAP inhibitors | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-10-04 | — | — | US | disclosed |
| US-9298096-B2 | Curable resin composition, cured product thereof, printed circuit board comprising the same, and method for producing the cured product | TAIYO INK MFG. CO., LTD. (JP) | 2016-03-29 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| US-20150010735-A1 | CURABLE RESIN COMPOSITION, CURED PRODUCT THEREOF, PRINTED CIRCUIT BOARD COMPRISING THE SAME, AND METHOD FOR PRODUCING THE CURED PRODUCT | TAIYO INK MFG. CO., LTD. (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford- Burnham Medical Reseach Institute (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2817292-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | Sanford-Burnham Medical Research Institute (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013126608-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011551-A1 | SULFONAMIDE COMPOUNDS AND USES AS TNAP INHIBITORS | TNNI3, TNKS1BP1, TNNT2 | ALPL 503/4885ALDH1A1 3674/4885MAPK1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.